PCN64 Cost-Effectiveness of Pembrolizumab (KEYTRUDA®) in Combination with Chemotherapy for First-LINE Treatment of Metastatic Squamous NON-SMALL Cell LUNG Cancer (NSCLC) in France
| Autor: | Chouaid, C., Bensimon, L., Tardu, J., Millier, A., Insinga, R., Rai, A., Levy-Bachelot, L., Levy, P. |
|---|---|
| Zdroj: | In Value in Health December 2020 23 Supplement 2:S433-S433 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect